DelveInsight’s, “Castrate Resistant Prostrate Cancer Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook

Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report

• In May 2025, Pfizer announced a study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician’s choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.
• In May 2025, Bayer conducted a study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy.
• In May 2025, Novartis Pharmaceuticals organized a study is to assess the efficacy, tolerability, safety, pharmacokinetic (PK) and dosimetry of 177Lu-PSMA-617, in participants with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in Japan. Furthermore, the safety, PK and dosimetry of 68Ga-PSMA-11 (PSMA imaging agent) are assessed in the same study.
• In May 2025, Janssen Research & Development LLC announced a study that consists of 4 phases: a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), a Follow-up Phase (every 3 months after end of treatment visit), and a Long-term Extension Phase (until participants no longer derive benefit from treatment or until further notification on different means of study treatment). Participants will be monitored for safety during the study period, and up to 30 days after the last dose of study drug.
• In May 2025, Celgene conducted a study is to compare the efficacy and safety of BMS-986365 versus the investigator’s choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
• DelveInsight’s Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
• The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
• Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.

Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs

Castrate Resistant Prostrate Cancer Emerging Drugs

• Niraparib: Janseen

Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.

• Nivolumab: Bristol-Myers Squibb

Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.

The Castrate Resistant Prostrate Cancer Pipeline analysis report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Castrate Resistant Prostrate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Castrate Resistant Prostrate Cancer Treatment.
• Castrate Resistant Prostrate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Castrate Resistant Prostrate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Castrate Resistant Prostrate Cancer market.

Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs

Castrate Resistant Prostrate Cancer Companies

Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.

Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers

Scope of the Castrate Resistant Prostrate Cancer Pipeline Report

• Coverage- Global
• Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
• Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
• Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Castrate Resistant Prostrate Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Castrate Resistant Prostrate Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Niraparib: Janseen
11. Mid Stage Products (Phase II)
12. ZEN003694: Newsoara Biopharma
13. Early Stage Products (Phase I)
14. EPI7386: ESSA Pharma
15. Pre-clinical and Discovery Stage Products
16. Drug Name: Company Name
17. Inactive Products
18. Castrate Resistant Prostrate Cancer Key Companies
19. Castrate Resistant Prostrate Cancer Key Products
20. Castrate Resistant Prostrate Cancer- Unmet Needs
21. Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
22. Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
23. Castrate Resistant Prostrate Cancer Analyst Views
24. Castrate Resistant Prostrate Cancer Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/castrate-resistant-prostrate-cancer-pipeline-insight